LAT CAB (2021-present)
The LAT CAB is a new cross-disease long-acting technologies (LAT) community advisory board focused on malaria, the hepatitis C virus, and latent TB infection.
Materials in this section
About
LAT CAB reviews the state of treatment research, contributes to research protocols, and engages in the research and development process for long-acting technologies for malaria, HCV, and LTBI. More
Community Call to Action on Equitable Access to Long-Acting Therapies
The growing pipeline for LAT and their potential to accelerate various disease elimination goals warrants global community mobilization to ensure equitable access to these therapies. More
LAT CAB Brochure
Learn about LAT CAB, Longevity project and meet the LAT CAB community experts. More
Community Mobilization to Ensure Health Systems’ Readiness for Long-Acting Therapies - Webinar Recording Now Available Online
Webinar organized by Treatment Action Group, INPUD and AfroCAB. More
The LAT CAB Responds to MedinCell and Medicines Patent Pool License on a New Long-Acting Malaria Formulation
Every minute a child in Sub-Saharan Africa dies from malaria; these are preventable deaths! More
MPP and MedinCell Sign Licence Agreement for mdc-STM, an Investigational Long-Acting Injectable Formulation to Fight Malaria Transmission
The non-exclusive licence agreement will enable MPP to support the identification of suitable partners for the development and commercialisation of mdc-STM. More
LAT CAB Video Presentation
In a video, LAT CAB members describe the goal of the CAB, and how long-acting therapies for malaria, latent TB prevention and HCV cure will benefit affected communities. More
Scientists Create Long-Acting Injectable Drug Delivery System for TB
Researchers showed in vivo efficacy of a long-acting injectable formulation of the TB drug rifabutin. More
Long-Acting Technologies Trials Tracker for Hepatitis C, Opioid Use and Overdose Prevention Therapy, and Malaria
TAG released a trials tracker providing information on the development of long-acting HCV, malaria, and opioid use and overdose prevention therapy formulations. More
LAT CAB Calls on AbbVie, Licensed Generic Manufacturers of G/P, and the Medicines Patent Pool to Fulfill their Commitment to Make Generic HCV Treatment Widely Available
Four years after MPP and AbbVie came to agreement on a voluntary license authorizing MPP to sublicense G/P to generic manufacturers, generic G/P is not available anywhere. More
